Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.
about
Bisphosphonate therapy in pediatric patientsHovenia dulcis Thunb extract and its ingredient methyl vanillate activate Wnt/β-catenin pathway and increase bone mass in growing or ovariectomized miceBreaking new ground to build boneLack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)].Intermittent parathyroid hormone improve bone microarchitecture of the mandible and femoral head in ovariectomized rats.Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survivalIntravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect.Anabolic agents and bone qualityEuodia sutchuenensis Dode extract stimulates osteoblast differentiation via Wnt/β-catenin pathway activationDelayed short-course treatment with teriparatide (PTH(1-34)) improves femoral allograft healing by enhancing intramembranous bone formation at the graft-host junctionSynthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidismTeriparatide in Fracture Non-Unions.Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor.NELL-1 injection maintains long-bone quantity and quality in an ovariectomy-induced osteoporotic senile rat model.Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm.Anabolic skeletal therapy for osteoporosis.Enhancement of fracture healing with parathyroid hormone: preclinical studies and potential clinical applications.PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation.Malignant myeloma in a patient after treatment for osteoporosis with teriparatide; a rare coincidenceParathyroid hormone/parathyroid hormone-related peptide regulate osteosarcoma cell functions: Focus on the extracellular matrix (Review).Adjuvant Teriparatide Therapy for Surgical Treatment of Femoral Fractures; Does It Work?Recombinant PTH associated with hypercalcaemia and renal failure.Carcinogenicity assessments of biotechnology-derived pharmaceuticals: a review of approved molecules and best practice recommendations.Parathyroid Hormone-Related Protein, Its Regulation of Cartilage and Bone Development, and Role in Treating Bone Diseases.Dormancy and growth of metastatic breast cancer cells in a bone-like microenvironment.Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.Preparation and evaluation of parathyroid hormone incorporated CaP coating via a biomimetic method.Hypoparathyroidism: is it time for replacement therapy?Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia.The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers.In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.Synthesis and in vitro bone cell activity of analogues of the cyclohexapeptide dianthin G.Structure activity relationship study on the peptide hormone preptin, a novel bone-anabolic agent for the treatment of osteoporosis.A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
P2860
Q26830702-26D0F86B-D28D-4578-8600-B9F74D5D7052Q28538976-7CE1E542-1605-4F2D-B25B-B435C8EA6EAFQ30443900-DBF83ECA-01E3-4741-BB60-83AD7A03F8F2Q33358285-AA8A78AC-47CD-46AA-8AFB-2BB67F5EF574Q33602111-4F83FF92-2987-4247-9988-C8DE356CBBC5Q33910434-DAD550E5-8668-4FEE-B59C-4ECD4C3E87EFQ33973902-F9D74D5B-12D6-4B2F-9B7C-71C81741DE60Q35078764-9B474BC9-00B2-4422-8291-026A7D376E78Q35152942-C1E1281B-6050-4EA6-AA7A-0D8812C7BA9FQ35659476-A5027AC7-804B-4A78-BAF8-F2A31552A923Q35744474-D01BA291-5F2D-4BE0-8147-1FBBB127FA50Q36116568-D104E37C-6787-4302-80FF-B5EFEE9E355CQ36372640-ED516C5F-C544-4DD9-8814-626E32F98C43Q36525894-874E9D1D-AE3B-414D-A4EF-C0A14B6C2328Q36599592-EFFCE74D-9FB7-4FB7-84EC-0F6E24C1D259Q36658955-38E8EB72-4FE9-4AE0-AEF3-F12F9F2AF9B5Q36764005-7231F11F-7398-4C44-81DB-46653C899ADDQ37166823-828DB46F-B7EE-47FE-A057-76B193CCCEFEQ37202913-2CB920AF-7399-418D-92C5-531E98B8C1F4Q37255459-5B706155-D971-4024-9259-EAFC70471E9FQ37345110-F3AE2CDD-E93A-4B55-91A6-50EA30A75DE0Q37391528-E136BD70-C31C-495D-BE97-02D701A3B3BEQ37753534-E901D819-7092-42B9-9EEF-64FA70D2AEC6Q38824663-8292D4C5-1EE0-467B-AC15-7669735F6808Q38902403-5625DAF6-1E59-4F54-8C4E-886DE7680EE6Q38999733-29B7A8B1-4C87-4601-BB60-4ED227DBE385Q39768330-CC02AE04-53AB-49F9-8266-B90E3B82C58BQ43066913-F1838FBE-D1DD-4313-BBA2-B2B88D9F5B13Q47612372-274413D5-B141-4B17-BA16-5B069E2C5CB8Q47783798-087A5E11-82FA-4175-9731-AAEBE5CC0C86Q50995497-FC74411C-F26E-406C-B36C-FA02C122A51BQ53155600-CE395A33-4817-4FC5-B45F-89335A0CD907Q53755539-AED50774-2F27-4656-AC3D-1928935A47CEQ53783337-30717AC4-5591-4179-934C-7B1FAC9F4274
P2860
Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Teriparatide [human PTH(1-34)] ...... the treatment of osteoporosis.
@ast
Teriparatide [human PTH(1-34)] ...... the treatment of osteoporosis.
@en
type
label
Teriparatide [human PTH(1-34)] ...... the treatment of osteoporosis.
@ast
Teriparatide [human PTH(1-34)] ...... the treatment of osteoporosis.
@en
prefLabel
Teriparatide [human PTH(1-34)] ...... the treatment of osteoporosis.
@ast
Teriparatide [human PTH(1-34)] ...... the treatment of osteoporosis.
@en
P356
P1476
Teriparatide [human PTH(1-34)] ...... the treatment of osteoporosis.
@en
P2093
Armen H Tashjian
Robert F Gagel
P304
P356
10.1359/JBMR.051023
P577
2005-11-11T00:00:00Z